Inhibitory Control of Medium Spiny Neurons
中型多棘神经元的抑制控制
基本信息
- 批准号:7405633
- 负责人:
- 金额:$ 1.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-12-06 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:Action PotentialsAgonistAxonCellsClassConfocal MicroscopyCorpus striatum structureDiseaseDopamineDopamine D2 ReceptorDoseDrug AddictionEnsureExcitatory Postsynaptic PotentialsFamilyFire - disastersFrequenciesFunctional disorderFutureGilles de la Tourette syndromeGlobus PallidusGreen Fluorescent ProteinsHuntington DiseaseInjection of therapeutic agentInterneuronsLiteratureMeasuresMediatingModalityMotorMouse StrainsMovementMuscle RigidityN-Methyl-D-Aspartate ReceptorsN-MethylaspartateNeuronsOutputParkinson DiseasePatternPopulationPropertyProteinsReceptor ActivationRegulationReportingRestRest TremorRoleSignal TransductionSliceStreamSubstantia nigra structureSymptomsSynaptic ReceptorsSystemTardive DyskinesiaTestingTherapeuticThinkingTimeWhole-Cell Recordingsaddictiondesignimprovedmotor impairmentnerve supplynervous system disordernovel therapeuticspostsynapticreceptorresearch studyresponseselective expressiontherapeutic targetvoltage
项目摘要
DESCRIPTION (provided by applicant): This project aims to compare phasic and tonic GABAA receptor-mediated currents and the receptor subtypes that mediate them in striatopallidal versus striatonigral medium spiny neurons (MSNs). MSNs are GABAergic neurons which make up 95% of the cells in the striatum. They primarily receive their inhibitory input from local GABAergic interneurons and axon collaterals of neighboring MSNs. The striatonigral MSNs project to the substantia nigra, express dopamine Dl receptors and are thought to facilitate movement whereas the striatopallidal MSNs project to the globus pallidus, express dopamine D2 receptors and are thought to inhibit movement. Parkinson's disease (PD) is a neurological disorder that results from a loss of DA innervation to the striatum and is characterized by impaired initiation of movement, resting tremor, postural instability and rigidity. Although the underlying mechanism remains unknown, an abundance of studies have suggested that the motor impairments seen in PD arise from an overactive output of the D2 positive MSNs that follows loss of dopaminergic innervation. It is unclear why the increased output is selective for the striatopallidal MSNs, however, identifying ways to selectively reduce the activity of the striatopallidal MSNs holds significant therapeutic potential for the treatment of the motor symptoms in PD. For this study, we will utilize corticostriatal slices made from two strains of mice which selectively express green fluorescent protein in either Dl expressing or D2 expressing cells to identify unique properties of receptors that mediate inhibitory currents in these cells. The properties of the GABAA receptors which mediate both the phasic and the tonic inhibition as well as the function of these currents on cell excitability and NMDA receptor activation will be assessed using single cell electrophysiological recordings in conjunction with immunofluoresence with confocal microscopy. In addition to potentially identifying new therapeutic targets in the GABAA receptor family for treatment of PD, the results of this study will significantly improve the understanding of striatal circuitry. This understanding is fundamental for future progress in treatment of PD as well as other striatal disorders like Huntington's disease, Tourette's, tardive dyskinesia and drug addiction.
描述(由申请人提供):本项目旨在比较纹状体苍白球与纹状体黑质中型棘神经元(MSN)中的阶段性和紧张性GABAA受体介导的电流以及介导它们的受体亚型。MSN是GABA能神经元,占纹状体细胞的95%。它们主要从邻近MSN的局部GABA能中间神经元和轴突侧支接收其抑制性输入。纹状体黑质MSN投射到黑质,表达多巴胺D1受体,并且被认为促进运动,而纹状体苍白球MSN投射到苍白球,表达多巴胺D2受体,并且被认为抑制运动。帕金森病(PD)是一种神经系统疾病,其由纹状体的DA神经支配的丧失引起,并且特征在于运动开始受损、静止性震颤、姿势不稳定和僵硬。虽然潜在的机制仍然未知,但大量的研究表明,PD中观察到的运动障碍是由多巴胺能神经支配丧失后D2阳性MSN的过度活跃输出引起的。目前还不清楚为什么增加的输出是选择性的纹状体的MSNs,然而,确定的方法来选择性地减少纹状体的MSNs的活动具有显着的治疗潜力的运动症状的治疗PD。对于本研究,我们将利用从两个品系的小鼠制备的皮质纹状体切片来鉴定介导这些细胞中的抑制电流的受体的独特性质,所述两个品系的小鼠在表达D1或表达D2的细胞中选择性地表达绿色荧光蛋白。将使用单细胞电生理记录结合免疫荧光和共聚焦显微镜来评估介导阶段性和强直性抑制的GABAA受体的特性以及这些电流对细胞兴奋性和NMDA受体激活的功能。除了可能在GABAA受体家族中找到治疗PD的新治疗靶点外,本研究的结果还将显着提高对纹状体回路的了解。这一认识对于帕金森病以及其他纹状体疾病如亨廷顿病、图雷特氏病、迟发性运动障碍和药物成瘾的治疗的未来进展至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kristen Kathleen Foster其他文献
Kristen Kathleen Foster的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kristen Kathleen Foster', 18)}}的其他基金
Simple, Home-use, neurostimulAtion tReatment for Parkinson's disease dEmeNtia (SHARPEN)
简单的家用神经刺激疗法治疗帕金森病痴呆 (SHARPEN)
- 批准号:
10697178 - 财政年份:2023
- 资助金额:
$ 1.39万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 1.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 1.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 1.39万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 1.39万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 1.39万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 1.39万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 1.39万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 1.39万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 1.39万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 1.39万 - 项目类别:














{{item.name}}会员




